The BMT CTN, sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), both of the National Institutes of Health (NIH), partners with numerous entities including academic institutions, non-profit organizations and pharmaceutical and biotechnology companies. Partner support ranges from contribution of a study drug and other in-kind donations, support of ancillary studies, and formal study collaborations, including registration studies.
Partnership with the BMT CTN allows input from and endorsement by key opinion leaders in transplantation and cell therapy, thereby enhancing study design and providing an opportunity for higher study enrollments. BMT CTN studies enroll patients from 20 Core Centers and 75 Affiliate Centers; which conduct more than 88% of US transplant and cell therapy procedures annually. Collaborations with partners leverage a well-functioning BMT CTN infrastructure, developed over more than 20 years, including the BMT CTN Steering and Executive Committees, an NHLBI Protocol Review Committee, NHLBI Data and Safety Monitoring Boards, and BMT CTN Technical Committees.
These vital partnerships lead to significant advances in cell and gene therapy research. To learn more about current or past partnerships, please visit the BMT CTN Studies page.
If you are interested in learning more about the BMT CTN, please complete this form to Connect With Us.